Further, SAS (an FDA approved drug that is capable of inhibiting SLC7A11) was shown to exhibit a significant radiosensitizing effect in both cell line-derived xenografts (CDXs) and patient-derived xenografts (PDXs) of ovarian cancer and KEAP1 mutant lung cancer; importantly, ferroptosis inhibitor treatment confirmed that SAS-mediated radiosensitization was indeed mediated by ferroptosis induction (Lang et al., 2019; Lei et al., 2020). Here, KEAP1 is linked to lung carcinoma.